BALKAN MEDICAL JOURNAL, vol.32, no.4, pp.388-396, 2015 (SCI-Expanded, Scopus, TRDizin)
Background: Gastrointestinal stromal tumors (GIST) have KIT or platelet-derived growth factor receptor a (PDGFR alpha) mutations affecting receptor tyrosine kinase activity and do not benefit from classic treatment regimens.